Ranbaxy signs licence deal with S. Korean firm
BANGALORE, Sept 17 |
BANGALORE, Sept 17 (Reuters) - Indian drug maker Ranbaxy Laboratories Ltd (RANB.BO) said on Thursday it had entered into a licensing agreement with South Korean firm Medy-Tox Inc for selling a cosmetic product in India. Ranbaxy will launch Medy-Tox's anti-ageing medicine Neuronox in India to boost its presence in the dermatological segment, said a company statement. (Reporting by Sumeet Chatterjee; Editing by John Mair)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters